Hepatocarcinoma clinical trials

Explore recruiting hepatocarcinoma clinical trials.

Recruiting hepatocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

Spain, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, randomized, double-blind, comparative clinical trial to assess the efficacy of Zinc Acexamate versus a placebo in improving the prognosis of patients with advanced chronic liver disease (cACLD).

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

PHITT: Paediatric Hepatic International Tumour Trial

Poland, Germany, France, Belgium, Ireland, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tumor types

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I DXd) in subjects with recurrent or metastatic solid tumors

Italy, France, Poland, Germany, Spain, Belgium +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Hepatocarcinoma trials by city

Hepatocarcinoma in Toronto Hepatocarcinoma in Vancouver Hepatocarcinoma in Montreal Hepatocarcinoma in Calgary Hepatocarcinoma in Edmonton Hepatocarcinoma in Ottawa Hepatocarcinoma in Winnipeg Hepatocarcinoma in Quebec City Hepatocarcinoma in Hamilton Hepatocarcinoma in Kitchener Hepatocarcinoma in London Hepatocarcinoma in Halifax Hepatocarcinoma in New York Hepatocarcinoma in Los Angeles Hepatocarcinoma in Chicago Hepatocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease